Use of bortezomib for prevention and treatment of rejection in sensitized patients.
We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.
Hartono
Choli
C
Department of Transplantation Medicine, Weill Cornell Medical College/New York-Presbyterian Hospital, New York, New York, USA.
Lubetzky
Michelle
M
Aull
Meredith J
MJ
Saal
Stuart
S
Figueiro
Jose
J
Kapur
Sandip
S
Dadhania
Darshana
D
D000328:Adult; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood* / Q000187:drug effects; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D010956:Plasmapheresis; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D055815:Young Adult
D001897:Boronic Acids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib